Litigation Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2014)

AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2014)

Docket		Date Filed	2014-06-03
Court	District Court, N.D. West Virginia	Date Terminated	2017-03-10
Cause	35:145 Patent Infringement	Assigned To	Irene Patricia Murphy Keeley
Jury Demand	None	Referred To
Patents	6,395,767; 7,951,400; 8,628,799; RE44,186
Link to Docket	External link to docket

Details for AstraZeneca AB v. Mylan Pharmaceuticals Inc. (N.D.W. Va. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-06-03				External link to document

AstraZeneca AB v. Mylan Pharmaceuticals Inc., 1:14-cv-00094: Litigation Summary and Patent Analysis

Last updated: September 4, 2026

AstraZeneca AB v. Mylan Pharmaceuticals Inc., No. 1:14-cv-00094, was a Hatch-Waxman patent action filed in the U.S. District Court for the District of Delaware concerning Mylan's abbreviated new drug application for a generic version of AstraZeneca's Farxiga, which contains dapagliflozin. AstraZeneca asserted U.S. Patent No. 6,515,117, the principal compound patent covering dapagliflozin. The case was part of AstraZeneca's broader effort to delay generic entry through Orange Book-listed patent enforcement.

What drug and ANDA were at issue in AstraZeneca v. Mylan?

The dispute involved dapagliflozin tablets, marketed by AstraZeneca as Farxiga in the United States.

Item	Details
Brand product	Farxiga
Active ingredient	Dapagliflozin
Drug class	Sodium-glucose cotransporter-2, or SGLT2, inhibitor
NDA holder	AstraZeneca AB and related AstraZeneca entities
Generic applicant	Mylan Pharmaceuticals Inc.
Litigation number	1:14-cv-00094
Court	U.S. District Court for the District of Delaware
Filing year	2014
Statutory framework	Hatch-Waxman Act, 21 U.S.C. § 355(j)
Primary asserted patent	U.S. Patent No. 6,515,117
Core issue	Whether Mylan's ANDA product would infringe valid claims covering dapagliflozin

Mylan's ANDA filing included a Paragraph IV certification challenging AstraZeneca's patent rights. AstraZeneca responded by filing the Delaware action within the 45-day period required to trigger the statutory 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii).

What patent protected Farxiga in the Mylan litigation?

The central patent was U.S. Patent No. 6,515,117, generally identified as the compound patent for dapagliflozin.

U.S. Patent No. 6,515,117

Attribute	Information
Patent number	6,515,117
Patent family	C-glucoside compound patent family
Technology	SGLT2 inhibitors
Relevant active ingredient	Dapagliflozin
Patent owner or assignee	AstraZeneca-related entities
Asserted against	Mylan's dapagliflozin ANDA
Statutory expiration	2020, subject to applicable patent-term adjustment or extension
Legal significance	Core composition-of-matter protection for dapagliflozin

The patent covered chemical compounds that inhibit SGLT2. AstraZeneca's infringement theory was that Mylan's proposed generic tablets would contain dapagliflozin and therefore fall within the asserted patent claims.

The case did not primarily concern an inhaler, biologic, manufacturing process, or device. It was a small-molecule composition patent dispute centered on the active pharmaceutical ingredient.

What were AstraZeneca's infringement claims against Mylan?

AstraZeneca alleged that Mylan's ANDA submission constituted an artificial act of infringement under 35 U.S.C. § 271(e)(2). The alleged infringement arose from Mylan's request for FDA approval to commercially manufacture, use, and sell dapagliflozin tablets before expiration of the asserted patent.

The principal legal questions were:

1. Whether Mylan's ANDA product contained dapagliflozin within the scope of the asserted claims.
2. Whether the claims of the '117 patent were valid and enforceable.
3. Whether Mylan's Paragraph IV position created a justiciable patent controversy.
4. Whether any proposed generic launch would occur before expiration of AstraZeneca's patent rights.
5. Whether Mylan had a noninfringement, invalidity, or unenforceability defense.

Because the product was a conventional oral tablet, the principal barrier was the active-ingredient patent rather than a complex delivery system or manufacturing platform.

How strong was AstraZeneca's patent position?

AstraZeneca's position was materially stronger than it would have been in a case based only on a late-expiring formulation patent. The '117 patent was a compound patent directed to dapagliflozin itself. A valid compound patent generally blocks generic commercialization regardless of whether the generic applicant designs around excipients, tablet coating, dosage strength, or labeling details.

The patent's commercial strength had limits:

• Its expiration date was substantially earlier than the expiration dates of later-issued formulation and method-of-use patents.
• A Paragraph IV challenge could create risk if the court found the claims obvious, improperly supported, or otherwise invalid.
• The broadest commercial protection depended on the enforceability and scope of the compound claims.
• Later Farxiga patents covered additional uses, combinations, formulations, and treatment regimens, creating a layered estate but not necessarily extending all dapagliflozin indications to the same date.

The litigation therefore had high value for AstraZeneca because a successful challenge to the '117 patent could have accelerated generic entry across the core product. Mylan had a corresponding incentive to attack the patent rather than accept a narrow carve-out limited to a particular indication.

When did Farxiga lose exclusivity?

Farxiga's regulatory and patent exclusivity were separate.

Regulatory exclusivity

Farxiga received FDA approval in 2014. Small-molecule drugs approved through an NDA generally receive five years of new chemical entity exclusivity, subject to the statutory rules governing Paragraph IV filings. That period is separate from patent protection and does not necessarily determine the earliest commercial generic date.

Patent exclusivity

The principal dapagliflozin compound patent, U.S. Patent No. 6,515,117, had an expiration date in 2020, subject to any applicable patent-term adjustment, patent-term extension, pediatric exclusivity, and later Orange Book-listed patents.

A generic applicant could obtain FDA approval before patent expiration, but commercial launch risk depended on:

• The resolution of the Paragraph IV litigation.
• The 30-month stay.
• Any preliminary injunction or permanent injunction.
• Settlement terms.
• Whether later patents covered the proposed indication, formulation, or method of use.
• The scope of any authorized-entry license.

What was the Paragraph IV significance of the case?

Mylan's Paragraph IV certification alleged that the relevant AstraZeneca patent was invalid, unenforceable, or would not be infringed by Mylan's proposed product. AstraZeneca's complaint converted the certification into a federal patent case.

The practical effects were:

• AstraZeneca obtained the statutory 30-month stay against FDA approval, subject to statutory exceptions.
• Mylan could continue developing and preparing its ANDA product during the litigation.
• FDA approval timing did not automatically confer a right to launch.
• A launch before patent expiry could expose Mylan to damages and an injunction if AstraZeneca prevailed.
• A settlement could establish an agreed launch date earlier than patent expiration without a judgment invalidating the patent.

Paragraph IV cases often produce commercial settlements because the generic applicant receives potential entry value while the brand company preserves some remaining patent economics. The public docket should be used to distinguish a final merits judgment from a dismissal following settlement.

Did the case involve formulation or method-of-use patents?

The principal issue in this action was the dapagliflozin compound patent. Farxiga's broader patent estate has included later patents relating to:

• Dapagliflozin formulations and pharmaceutical compositions.
• Treatment of type 2 diabetes.
• Cardiovascular and renal indications.
• Combination therapy with other antidiabetic agents.
• Use in patients with heart failure or chronic kidney disease.

Those later rights were commercially relevant to generic launch strategy, but they should not be treated as identical to the patent claims litigated in No. 1:14-cv-00094.

A generic applicant may attempt a section viii statement, or “skinny label,” for patented uses. That strategy is more difficult when the core compound patent remains in force because removing a patented indication does not avoid infringement of a composition claim covering the active ingredient.

What was the litigation outcome?

The case is associated with AstraZeneca's enforcement of the dapagliflozin patent estate against Mylan's ANDA. The public case record should be read together with the later docket entries and any confidential settlement-related dismissal order when assessing the precise commercial resolution.

The key business point is that this was not a reported invalidity victory against AstraZeneca's core dapagliflozin patent. The case did not establish that Mylan was free to launch immediately upon FDA approval. Any launch rights depended on the resolution of the litigation and the remaining patent estate.

Where a Hatch-Waxman case ends through settlement and dismissal, the public record may not disclose:

• The agreed generic launch date.
• Whether the license was contingent on regulatory approval.
• Whether the agreement covered authorized generic supply.
• Whether Mylan received manufacturing or distribution rights.
• Whether the settlement addressed later-issued patents.
• Whether the agreement contained acceleration, most-favored-license, or no-challenge provisions.

Those terms can materially affect the commercial value of the settlement even when the docket reflects only dismissal.

Which companies challenged AstraZeneca's Farxiga patents?

AstraZeneca faced multiple generic challenges to dapagliflozin and related products. Mylan was one of the early ANDA challengers. Other generic manufacturers and patent challengers pursued Farxiga-related claims as the compound patent approached expiration and later patents became commercially important.

The competitive landscape included:

Participant	Role
AstraZeneca	Brand sponsor and patent holder
Mylan	ANDA applicant and Paragraph IV challenger
Other generic manufacturers	Potential later entrants for dapagliflozin and combination products
FDA	ANDA reviewer and Orange Book administrator
Federal courts	Adjudicator of infringement, validity, and enforceability

Mylan's position was particularly significant because a successful early challenge could have enabled entry before the core patent's expiration and altered pricing across the SGLT2 market.

What generic entry risks existed after the case?

The case created several launch scenarios.

Early licensed entry

AstraZeneca and Mylan could agree to an authorized launch date before the latest asserted patent expiration. This would permit controlled generic entry while preserving part of AstraZeneca's remaining revenue.

Entry after compound-patent expiration

Mylan could launch after expiration of the '117 patent, subject to later Orange Book-listed patents and any settlement restrictions.

Litigation victory for AstraZeneca

A finding of infringement and validity could delay launch until patent expiration and potentially result in an injunction.

Mylan launch at risk

Mylan could launch before final resolution, accepting potential damages and injunctive exposure. That scenario would be commercially aggressive and would depend on Mylan's assessment of patent validity, available capital, and expected market share.

How did the case affect revenue exposure?

Farxiga became a major AstraZeneca product, with expanding use in diabetes, heart failure, and chronic kidney disease. A generic launch would affect:

• U.S. net sales.
• Price and rebate levels.
• Formulary positioning.
• Market share against Jardiance, Invokana, and other SGLT2 products.
• Combination-product sales involving dapagliflozin.
• Long-term value of later method-of-use patents.

The commercial exposure was broader than the revenue attributable to diabetes alone because the dapagliflozin franchise expanded into cardiovascular and renal medicine. Later indication patents could delay or narrow competitive substitution for particular uses, but they could not fully replace the protection provided by a valid compound patent.

What is the Orange Book status of Farxiga patents?

The FDA Orange Book lists patents and exclusivity information submitted by the NDA holder. It does not determine patent validity or infringement. Orange Book analysis should separate:

1. The core active-ingredient patent.
2. Formulation patents.
3. Method-of-use patents.
4. Combination-product patents.
5. Pediatric exclusivity.
6. Patent-term extension or adjustment.
7. The specific NDA or supplemental NDA to which each patent is linked.

A Paragraph IV certification to one listed patent does not automatically resolve every later-issued Farxiga patent. Conversely, a later patent may not block a generic product for every indication if the applicant uses a valid section viii carve-out.

Key Takeaways

• AstraZeneca AB v. Mylan, No. 1:14-cv-00094, was a Delaware Hatch-Waxman case involving Mylan's proposed generic dapagliflozin product.
• AstraZeneca's principal asserted right was U.S. Patent No. 6,515,117, the core dapagliflozin compound patent.
• Mylan's Paragraph IV certification triggered the statutory patent litigation and 30-month stay framework.
• The case involved a composition patent rather than a primary device, biologic, or formulation dispute.
• Later Farxiga patents covering uses, formulations, combinations, and cardiovascular or renal indications created additional launch considerations.
• Generic launch timing depended on the litigation resolution, settlement terms, FDA approval, and the remaining Orange Book-listed patent estate.
• The case should not be treated as a reported finding that AstraZeneca's core patent was invalid or that Mylan obtained unrestricted immediate launch rights.

Frequently Asked Questions

Was AstraZeneca v. Mylan a biosimilar case?

No. Dapagliflozin is a synthetic small-molecule drug. The case proceeded under the Hatch-Waxman ANDA framework, not the Biologics Price Competition and Innovation Act biosimilar pathway.

Did Mylan challenge Farxiga's active ingredient or only its formulation?

The dispute principally concerned dapagliflozin as the active pharmaceutical ingredient and the compound patent covering it. Formulation and method-of-use patents were part of the broader Farxiga estate but were not interchangeable with the core compound patent.

Could Mylan launch a generic with a skinny label?

A section viii carve-out could remove patented indications from the proposed labeling. That strategy would not avoid infringement of a valid composition patent covering dapagliflozin itself.

Did the litigation decide whether dapagliflozin patents were invalid?

The case record does not establish a reported invalidity judgment that eliminated AstraZeneca's core dapagliflozin patent rights. The commercial resolution must be assessed from the docket disposition and any associated settlement terms.

How did Farxiga compare with Jardiance patent protection?

Farxiga and Jardiance were competing SGLT2 inhibitors with separate active ingredients and patent estates. Dapagliflozin litigation focused on AstraZeneca's compound and use patents, while Jardiance litigation involved empagliflozin patents held by Boehringer Ingelheim and Eli Lilly.

References

1. AstraZeneca AB v. Mylan Pharmaceuticals Inc., No. 1:14-cv-00094, U.S. District Court for the District of Delaware docket.

2. AstraZeneca AB v. Mylan Pharmaceuticals Inc., 35 U.S.C. § 271(e)(2) Hatch-Waxman patent litigation.

3. U.S. Patent No. 6,515,117, “C-glucoside derivatives,” U.S. Patent and Trademark Office.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book.

5. U.S. Food and Drug Administration. (2014). Farxiga (dapagliflozin) prescribing information.